GILD
GILD
NASDAQ · Biotechnology

Gilead Sciences Inc

S&P 500 Nasdaq 100 Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks Best Dividend Stocks
$129.58
-2.48 (-1.88%)
As of May 16, 1:01 AM ET ·
Financial Highlights (FY 2026)
Revenue
29.06B
Net Income
8.40B
Gross Margin
78.8%
Profit Margin
28.9%
Rev Growth
+2.6%
D/E Ratio
1.10
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 78.8% 78.8% 53.5% 53.5%
Operating Margin 34.0% 30.6% -33.3% -35.4%
Profit Margin 28.9% 27.5% -32.6% -32.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 29.06B 28.33B 56.82B 62.77B
Gross Profit 22.91B 22.34B 30.40B 33.58B
Operating Income 9.89B 8.68B -18,927,955,656 -22,233,853,953
Net Income 8.40B 7.37B -18,545,178,243 -20,228,320,493
Gross Margin 78.8% 78.8% 53.5% 53.5%
Operating Margin 34.0% 30.6% -33.3% -35.4%
Profit Margin 28.9% 27.5% -32.6% -32.2%
Rev Growth +2.6% +2.6% -2.6% +18.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 42.01B 42.01B 23.22B 22.16B
Total Equity 38.24B 38.24B 127.95B 131.01B
D/E Ratio 1.10 1.10 0.18 0.17
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 10.25B 9.50B -26,008,242,356 -28,250,733,263
Free Cash Flow — — -20,166,967,145 -15,276,791,822